Next Science Ltd (NXS) - Total Liabilities
Based on the latest financial reports, Next Science Ltd (NXS) has total liabilities worth AU$10.02 Million AUD (≈ $7.09 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore NXS year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Next Science Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Next Science Ltd's total liabilities have evolved over time, based on quarterly financial data.
Next Science Ltd Competitors by Total Liabilities
The table below lists competitors of Next Science Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Societe d Exploration Miniere Vior Inc
V:VIO
|
Canada | CA$12.71 Million |
|
Ponni Sugars (Erode) Limited
NSE:PONNIERODE
|
India | Rs837.70 Million |
|
Aerodrome Group Ltd
TA:ARDM
|
Israel | ILA11.09 Million |
|
Softing AG
XETRA:SYT
|
Germany | €50.05 Million |
|
Hochschild Mining plc
LSE:HOC
|
UK | GBX1.28 Billion |
|
Aciselsan Acipayam Seluloz Sanayi Ve Ticaret AS
IS:ACSEL
|
Turkey | TL352.95 Million |
|
Shanghai Lingyun Industries Development Co Ltd
SHG:900957
|
China | $423.71 Million |
|
V-Tac Technology Co Ltd
TWO:6229
|
Taiwan | NT$978.22 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Next Science Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Next Science Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -17.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Next Science Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Next Science Ltd (2016–2024)
The table below shows the annual total liabilities of Next Science Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$5.77 Million ≈ $4.08 Million |
+13.63% |
| 2023-12-31 | AU$5.08 Million ≈ $3.59 Million |
-22.14% |
| 2022-12-31 | AU$6.52 Million ≈ $4.62 Million |
+121.78% |
| 2021-12-31 | AU$2.94 Million ≈ $2.08 Million |
-37.37% |
| 2020-12-31 | AU$4.70 Million ≈ $3.32 Million |
+40.70% |
| 2019-12-31 | AU$3.34 Million ≈ $2.36 Million |
+36.73% |
| 2018-12-31 | AU$2.44 Million ≈ $1.73 Million |
+336.36% |
| 2017-12-31 | AU$559.46K ≈ $395.85K |
+125.39% |
| 2016-12-31 | AU$248.22K ≈ $175.63K |
-- |
About Next Science Ltd
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides woun… Read more